PMC:7148425 / 1859-2101
Annnotations
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32300370-32113509-46535320 | 140-141 | 32113509 | denotes | 1 |
T12898 | 140-141 | 32113509 | denotes | 1 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T23 | 67-72 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
T24 | 81-87 | NCBITaxon:10239 | denotes | virals |
T57286 | 67-72 | CHEBI:23888;CHEBI:23888 | denotes | drugs |
T55368 | 81-87 | NCBITaxon:10239 | denotes | virals |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T11 | 169-170 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 67-72 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T12 | 0-242 | Sentence | denotes | Although much effort is currently directed at repurposing licensed drugs as anti-virals, particularly those with anti-inflammatory effects [1] this is usually viewed as a stop-gap measure and hopes are pinned on developing effective vaccines. |